Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma

被引：19

作者：

Davar D. ^{[1
]}

Socinski M.A. ^{[1
,3
]}

Dacic S. ^{[2
]}

Burns T.F. ^{[1
,4
]}

机构：

[1] University of Pittsburgh Medical Center, Division of Hematology-Oncology, Department of Medicine, Pittsburgh, PA

[2] University of Pittsburgh Medical Center, Division of Anatomic Pathology, 200 Lothrop Street, Office: PUH C608, Pittsburgh, 15213, PA

[3] University of Pittsburgh Cancer Institute, Division of Hematology-Oncology, 5150 Centre Avenue, 5th floor, Pittsburgh, 15232, PA

[4] University of Pittsburgh Cancer Institute, Division of Hematology-Oncology, 5117 Centre Avenue, Office: Suite 2.18e, Pittsburgh, 15232, PA

来源：

Experimental Hematology & Oncology | / 4卷 / 1期

关键词：

Adenocarcinoma; KRAS mutant; Lung cancer; Nivolumab; Programmed death receptor-1 (PD-1);

D O I：

10.1186/s40164-015-0029-7

中图分类号：

学科分类号：

摘要：

The programmed death 1 (PD-1) receptor is expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 normally expressed by infiltrating immune cells in response to viral infection. The PD-1/PD-L1 axis is a negative inhibitory pathway that down-regulates T-cells but is also used by tumors to evade anti-tumor immunity. Antibodies targeting PD-1/PD-L1 axis are capable of restoring functional anti-tumor immunity and have demonstrated efficacy in a broad range of tumor types including non-small cell lung cancer in both squamous and adenocarcinoma histologies. Ongoing issues affecting clinical development of these agents include assessment of response, optimal duration of therapy in excellent responders, predictive biomarkers and mechanisms of resistance. In this report, we describe a patient with advanced KRAS mutant heavily pretreated pulmonary adenocarcinoma who developed an excellent response after a single-dose of nivolumab. Pre-treatment tumor was found to have moderate CD3 and PD-L1 positivity by immunohistochemical staining. Evaluation of exceptional responders and non-responders are critical to furthering our understanding of the mechanisms of action (and resistance) to these agents. © 2015 Davar et al.

引用

共 18 条

[11] Gettinger S.N., Horn L., Gandhi L., Et al., Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, 33, 18, pp. 2004-2012, (2015)
[12] Gatalica Z., Snyder C., Maney T., Et al., Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type, Cancer Epidemiol Biomarkers Prev, 23, 12, pp. 2965-2970, (2014)
[13] Cierna Z., Mego M., Miskovska V., Et al., Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors, Ann Oncol., (2015)
[14] Gevensleben H., Dietrich D., Golletz C., Et al., The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer, Clin Cancer Res., (2015)
[15] Krupka C., Kufer P., Kischel R., Et al., Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE<sup>®</sup> antibody construct AMG 330: reversing a T-cell induced immune escape mechanism, Leukemia., (2015)
[16] Kohnke T., Krupka C., Tischer J., Knosel T., Subklewe M., Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab, J Hematol Oncol, 8, 1, (2015)
[17] Rizvi N.A., Hellmann M.D., Snyder A., Et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science., (2015)
[18] Tumeh P.C., Harview C.L., Yearley J.H., Et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 7528, pp. 568-571, (2014)

← 1 2 →